ReviewDrugs & aging2010
Optimal management of peptic ulcer disease in the elderly.
Review in Drugs & aging, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Efficacy of ilaprazole in the treatment of duodenal ulcers: a meta-analysis.World journal of gastroenterology · 2014Pooled it
- Antiperistaltic effect and safety of L-menthol for esophagogastroduodenoscopy in the elderly with contraindication to hyoscine-N-butylbromide.Scientific reports · 2022Trial
- Implementation of enhanced recovery after surgery (ERAS) protocols in elderly patients undergoing emergency surgery for perforated peptic ulcer: a comparative analysis.BMC gastroenterology · 2025Article
- Article
- Helicobacter pylori Eradication Treatment in Older Patients.Drugs & aging · 2024Review
- How peptic ulcer disease could potentially lead to the lifelong, debilitating effects of chronic fatigue syndrome: an insight.Scientific reports · 2021Article
- The number of household members as a risk factor for peptic ulcer disease.Scientific reports · 2021Article
- Non-steroidal anti-inflammatory drugs and gastroprotection in primary health care users.Medicine and pharmacy reports · 2020Article
- Gastrointestinal Tract Disorders in Older Age.Canadian journal of gastroenterology & hepatology · 2019Review
- Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer's disease.European journal of clinical pharmacology · 2017Article
- Evaluation of combined famotidine with quercetin for the treatment of peptic ulcer: in vivo animal study.Drug design, development and therapy · 2015Article
- Common GI Drug Interactions in the Elderly.Current treatment options in gastroenterology · 2014Article
- Helicobacter pylori infection in older people.World journal of gastroenterology · 2014Review
- Abdominal emergencies in the geriatric patient.International journal of emergency medicine · 2014Review
- Stress ulcer prophylaxis, thromboprophylaxis and coagulation management in patients with hip fractures.Wiener medizinische Wochenschrift (1946) · 2013Review
- Upper GI endoscopy in elderly patients: predictive factors of relevant endoscopic findings.Internal and emergency medicine · 2013Article
- Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients--focus on esomeprazole.Clinical interventions in aging · 2013Review
- Adverse drug events as a cause of hospitalization in older adults.Drug safety · 2012Review
- Acquired inhibitors: a special case of bleeding in older adults.Current gerontology and geriatrics research · 2012Article
- Gastrointestinal effects of aspirin.Nature reviews. Gastroenterology & hepatology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent data report that the incidence of peptic ulcer is decreasing in the general population; conversely, the rates of gastric and duodenal ulcer hospitalization and mortality remain very high in older patients. Two major factors that might explain this epidemiological feature in the elderly population are the high prevalence of Helicobacter pylori infection and the increasing prescriptions of gastroduodenal damaging drugs, including NSAIDs and/or aspirin (acetylsalicylic acid). The main goals for treating peptic ulcer disease in old age are to reduce recurrence of the disease and to prevent complications, especially bleeding and perforation. The available treatments for peptic ulcer are essentially based on gastric acid suppression with antisecretory drugs and the eradication of H. pylori infection. The aim of this article is to report the available data on clinical efficacy and tolerability of peptic ulcer treatments in elderly patients and provide recommendations for their optimal use in this special population. Proton pump inhibitor (PPI)-based triple therapies for 7 days are highly effective for the cure of H. pylori-positive peptic ulcers as well as for reducing ulcer recurrence. Antisecretory drugs are also the treatment of choice for NSAID- or aspirin-related peptic ulcers and are useful as preventive therapy in chronic users of NSAIDs and low-dose aspirin as antiplatelet therapy. Antisecretory PPI therapy has a favourable tolerability profile in geriatric patients; however, monitoring is suggested in older patients with frequent pulmonary infections, gastrointestinal malabsorption, unexplained chronic diarrhoea, osteoporosis or those taking concomitant cytochrome P450 2C19-metabolized medications. The overall approach to the geriatric patient should include a comprehensive geriatric assessment that ensures multidimensional evaluation of the patient in order to better define the clinical risk of adverse outcomes in the older patient with peptic ulcer and its complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.